Compare MIRM & PBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MIRM | PBF |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Integrated oil Companies |
| Sector | Health Care | Energy |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 3.5B |
| IPO Year | 2019 | 2012 |
| Metric | MIRM | PBF |
|---|---|---|
| Price | $100.65 | $35.58 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 11 |
| Target Price | ★ $102.64 | $31.18 |
| AVG Volume (30 Days) | 733.0K | ★ 2.9M |
| Earning Date | 02-26-2026 | 02-12-2026 |
| Dividend Yield | N/A | ★ 3.08% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $471,794,000.00 | ★ $29,544,100,000.00 |
| Revenue This Year | $55.91 | N/A |
| Revenue Next Year | $23.97 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 53.66 | N/A |
| 52 Week Low | $36.88 | $13.62 |
| 52 Week High | $105.74 | $41.48 |
| Indicator | MIRM | PBF |
|---|---|---|
| Relative Strength Index (RSI) | 64.68 | 61.08 |
| Support Level | $97.49 | $33.95 |
| Resistance Level | $105.74 | $36.12 |
| Average True Range (ATR) | 3.71 | 1.70 |
| MACD | -0.79 | 0.16 |
| Stochastic Oscillator | 62.01 | 86.75 |
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
PBF Energy Inc is an independent petroleum refiner and supplier of unbranded transportation fuels, heating oil, petrochemical feedstocks, lubricants, and other petroleum products in the United States. The company owns refineries in Delaware, Ohio, New Jersey, California, and Louisiana. The Company operates in two reportable business segments: Refining and Logistics. The Company's oil refineries are all engaged in the refining of crude oil and other feedstocks into petroleum products and are aggregated into the Refining segment. PBFX operates logistics assets such as crude oil and refined products terminals, pipelines and storage facilities. The Logistics segment consists solely of PBFX's operations.